Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107M
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
14.3M
-
Shares change
-
+8.09M
-
Total reported value, excl. options
-
$15.4M
-
Value change
-
+$8.74M
-
Put/Call ratio
-
0.05
-
Number of buys
-
35
-
Number of sells
-
-7
-
Price
-
$1.08
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q1 2025
53 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.3M shares
of 107M outstanding shares and own 13.4% of the company stock.
Largest 10 shareholders include Anson Funds Management LP (7.58M shares), VANGUARD GROUP INC (2.84M shares), GEODE CAPITAL MANAGEMENT, LLC (820K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (689K shares), BlackRock, Inc. (538K shares), CITADEL ADVISORS LLC (350K shares), STATE STREET CORP (277K shares), Opus Capital Group, LLC (240K shares), NORTHERN TRUST CORP (164K shares), and MORGAN STANLEY (66.5K shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.